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Abstract
A variety of vaccine platforms are under study for development of new vaccines for measles. Problems with past measles
vaccines are incompletely understood and underscore the need to understand the types of immune responses induced by
different types of vaccines. Detailed immune response evaluation is most easily performed in mice. Although mice are not
susceptible to infection with wild type or vaccine strains of measles virus, they can be used for comparative evaluation of
the immune responses to measles vaccines of other types. In this study we compared the immune responses in mice to a
new protective alphavirus replicon particle vaccine expressing the measles virus hemagglutinin (VEE/SIN-H) with a non-
protective formalin-inactivated, alum-precipitated measles vaccine (FI-MV). MV-specific IgG levels were similar, but VEE/SIN-
H antibody was high avidity IgG2a with neutralizing activity while FI-MV antibody was low-avidity IgG1 without neutralizing
activity. FI-MV antibody was primarily against the nucleoprotein with no priming to H. Germinal centers appeared, peaked
and resolved later for FI-MV. Lymph node MV antibody-secreting cells were more numerous after FI-MV than VEE/SIN-H, but
were similar in the bone marrow. VEE/SIN-H-induced T cells produced IFN-c and IL-4 both spontaneously ex vivo and after
stimulation, while FI-MV-induced T cells produced IL-4 only after stimulation. In summary, VEE/SIN-H induced a balanced T
cell response and high avidity neutralizing IgG2a while FI-MV induced a type 2 T cell response, abundant plasmablasts, late
germinal centers and low avidity non-neutralizing IgG1 against the nucleoprotein.
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Introduction
Measles remains a significant cause of morbidity and mortality
in young children, particularly in sub-Saharan Africa and Asia [1].
Because there is no animal reservoir and an efficacious live-
attenuated virus vaccine (LAV) is available, eradication has been
considered by global health organizations [1–3]. However, LAV is
neutralized by passively acquired maternal antibody and cannot
be administered effectively during the first months of life, thus both
complicating vaccine delivery with a need for an additional health
care visit and creating a variable window of susceptibility to
measles prior to vaccination [4,5]. Administration of larger
amounts of LAV to bolster vaccine virus replication in the face
of maternal antibody resulted in an unexpected late increase in
mortality [6,7]. Current approaches to improving measles vaccine
coverage include aerosol delivery of LAV [8] and development of
a new measles vaccine able to induce protective immunity in
children younger than 6 months of age [9–14]. Previous
experience with an inactivated vaccine that primed for more
severe disease requires a better understanding of the immune
responses to measles vaccines of different types before developing a
new measles vaccine.
Measles virus (MV) is a member of the Paramyxoviridae family in
the Morbillivirus genus and encodes 6 structural proteins,
including 2 surface glycoproteins, hemagglutinin (H) and fusion
(F). Non-envelope structural proteins include nucleocapsid (N),
matrix (M) and the replicase proteins, large and phosphoprotein.
MV was isolated in 1954 [15] and the first measles vaccines were
developed by the early 1960s [16–22]. Similar to the polio
vaccines developed a decade earlier, two strategies were employed-
virus attenuation and inactivation. Both LAV and an alum-
precipitated, formalin-inactivated MV vaccine (FI-MV) were
licensed in 1963. Subsequently, it was observed that some
individuals immunized with FI-MV were not protected from
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enhanced disease, termed atypical measles, characterized by high
fever, unusual petechial rash and pneumonitis [23–31]. Despite
progress, the immunologic basis for atypical measles remains
incompletely understood [32–34].
The efficacy of measles vaccines is highly dependent on the
ability to induce high-titer, long-lived neutralizing antibody, as
occurs after natural infection [35]. Infection induces antibody
against most viral proteins [36], but protection correlates with the
level of neutralizing antibody that is directed primarily against H
and to a lesser extent F [14,37–42]. After FI-MV immunization,
antibody titers waned quickly. Two-and-a-half years after
receiving a 3-dose course, over 40 percent of children no longer
had protective levels of antibody [23]. FI-MV also induced short-
lived, low-avidity MV-specific immunoglobulin G (IgG) in rhesus
macaques that were then prone to atypical measles on challenge
[33,34]. Studies of vaccinated mice offer the opportunity to
examine the nature of the immune response to FI-MV in more
detail.
Because LAV does not replicate in mice, this vaccine cannot be
used for comparative studies. However, one promising strategy for
new vaccine development is the use of alphavirus replicon particles
that can be studied in mice [43]. These vaccines contain the
alphavirus nonstructural genes, the 59 and 39 cis-active replication
sequences and the subgenomic promoter that directs expression of
a heterologous gene [44]. The replicon RNA is then packaged into
virus-like particles by providing the structural protein in trans [45–
47]. Several different alphaviruses are being developed as vectors
for a variety of vaccine antigens [48–50]. These vaccines undergo
only a single round of replication and circumvent the problem of
interference due to passively acquired maternal antibody because
the alphavirus particles will not be neutralized by pre-existing
antibody to the heterologous antigen [51]. In addition, these
vaccines have intrinsic adjuvant activity that has only been
partially characterized [52–54].
We have developed a chimeric alphavirus replicon vaccine [48]
utilizing the nonstructural genes from Venezuelan equine enceph-
alitis virus as a replicon expressing the MV H protein packaged
with Sindbis virus structural proteins to produce the replicon
particle vaccine VEE/SIN-H. This vaccine has recently been
shown to induce protective immunity in rhesus macaques [55].
To better understand the nature of the non-protective immune
response generated by FI-MV, we have used a mouse model to
compare the immune responses to FI-MV with the immune
response to VEE/SIN-H.
Results
MV-specific antibody responses after vaccination
Although mice are not susceptible to infection with MV or
LAV, they offer a well-characterized animal model for evaluating
immunogenicity of non-replicating vaccines [9,11,13,56–60]. Mice
were immunized subcutaneously with single doses of FI-MV or
VEE/SIN-H. MV-specific IgG was measured by enzyme
immunoassay (EIA) using a measles virus-infected Vero cell lysate
(MVL) as antigen (Fig. 1). The time course and magnitude of the
IgG response to FI-MV and VEE/SIN-H were similar (Fig. 1A).
However, the isotypes were different. FI-MV induced primarily
IgG1 antibody, suggesting type 2 T cell help (Fig. 1B), while VEE/
SIN-H elicited mostly IgG2a antibody, suggestive of type 1 T cell
help (Fig. 1C). MV-specific IgG3 was not detected for either group
(data not shown). Antibody avidity steadily improved in VEE/
SIN-H–immunized mice and at day 36 was significantly higher
(p,0.05) than that of antibody induced by FI-MV and remained
higher through day 82 (Fig. 1D). Plaque reduction neutralization
assays showed geometric mean titers .1:200 by day 20 and
.1:600 on day 80 for serum from VEE/SIN-H-immunized mice,
but no neutralization by serum from FI-MV mice (Fig. 1E).
VEE/SIN-H and FI-MV initiate germinal center reactions
with similar magnitude, but different kinetics
To determine whether the lack of production of avid antibody
against MV after FI-MV was due to a deficit in the formation of
germinal centers (GCs), dLNs were evaluated for numbers of GCs
(Fig. 2) and GC B cells (PNA
+CD19
+) (Fig. 3) after immunization.
Control mice were immunized with sheep red blood cells (SRBCs),
a complex T-dependent antigen that induces a robust GC reaction
[61,62], or with PBS. Histological examination showed few GCs at
day 7 after FI-MV immunization compared to immunization with
SRBC or VEE/SIN-H (Fig. 2B) and the GCs observed were not
well formed (Fig. 2A). Flow cytometry was used to quantify peanut
agglutinin (PNA)
+ B cells (Fig. 3A). On day 7, few PNA
+ CD19
+ B
cells were present in the dLNs of FI-MV–immunized mice
(0.96%), similar to the PBS control (0.14%), while the percentage
of GC B cells in the dLNs of VEE/SIN-H (5.6%) was similar to
SRBC-immunized mice (6.16%).
To determine the kinetics of the GC reaction in the dLNs, mice
were evaluated at multiple times after immunization (Fig. 3B). GC
B cells were most numerous 7–12 days after immunization for
VEE/SIN-H (5.65%) and SRBC (11.3%) but peak responses were
delayed in FI-MV–immunized mice with GC B cells first detected
on day 12 and reaching their maximum (6.95%) on day 20. In
addition to the delayed development, FI-MV–induced GCs
resolved later (day 56) than VEE/SIN-H-induced GCs (day 30),
showing similarity to SRBC-induced GCs (day 80). GC B cells
were detected in the spleens of SRBC–immunized mice but not
VEE/SIN-H or FI-MV–immunized mice (data not shown).
Antibody-secreting cells specific for MV are present in
short-lived and long-lived compartments
Antibody-secreting cells (ASCs) are generated in secondary
lymphoid tissues and may or may not acquire the ability to mature
into long-lived plasma cells and home to the bone marrow [63,64].
Total IgG ASCs increased in dLNs after immunization with a
peak at day 12 for both groups (Fig. 4A). MV-specific ASCs
peaked at day 20 for FI-MV and peaked and then plateaued
between days 12–40 for VEE/SIN-H (Fig. 4B). At day 20 the dLN
ASC response to FI-MV was 6-fold greater than it was for VEE/
SIN-H. Few ASCs were detected in the spleen for either vaccine
(data not shown). In the bone marrow, numbers of IgG-secreting
cells did not change (Fig. 4C), but small numbers of MV-specific
ASCs began to appear by day 20 in both groups (Fig. 4D, E). The
amount of MV-specific antibody secreted from individual bone
marrow plasma cells increased through day 125, as indicated by
the spot size, for VEE/SIN-H-immunized mice and through day
80 for FI-MV-immunized mice (Fig. 4F).
Specificity of the B cell response to individual MV
proteins
To determine why FI-MV–immunized mice did not develop
neutralizing antibody (Fig. 1E) despite seroconversion (Fig. 1A),
the specificity of serum IgG for individual MV proteins (H, F and
N) was determined (Fig. 5). As expected, VEE/SIN-H–immunized
mice showed a robust H-specific response and no response to F or
N. FI-MV-immunized mice developed no detectable H-specific
(Fig. 5A) or F-specific (Fig. 5B) IgG, but did develop antibody to N
(Fig. 5C). At day 125 after immunization, plasma cells in the bone
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VEE/SIN-H-immunized mice had substantial numbers of plasma
cells secreting antibody to H, while no H-specific plasma cells were
detected in the bone marrow of FI-MV–immunized mice.
MV-specific T cell responses in the draining lymph nodes
To compare T cell responses, draining lymph node (LN) cells
were assayed by ELISpot for IFN-c and IL-4-producing cells
directly ex vivo and after stimulation in vitro with MV antigen 7, 14
and 21 days after immunization (Fig. 6). During the peak response
at day 7, VEE/SIN-H, but not FI-MV, induced substantial
numbers of IFN-c (Fig. 6A) and IL-4 (Fig. 6B) spot-forming cells
(SFCs) that were detected directly ex vivo. Stimulation with MV
increased the numbers of cells from VEE/SIN-H–immunized
mice producing IFN-c and IL-4 and induced IFN-c and IL-4
expression by cells from FI-MV–immunized mice. dLN cells from
VEE/SIN-H–immunized mice predominantly produced IFN-c






















Figure 1. Measles virus-specific antibody response to immunization. Sera collected from individual mice immunized with VEE/SIN-H or FI-
MV were assessed for quantity and quality of MV-specific antibody. MV-specific total IgG (A), IgG1 (B) and IgG2a (C) were measured by EIA. Avidity of
MV-specific antibody was evaluated by a modified EIA and data are presented as an avidity index (D). Fifty percent plaque reduction neutralization
titers (PRNT) for the Chicago-1 strain of MV on Vero cells are expressed as geometric means (E). Data points represent the mean +/- S.D. of three
individual mice. (* P,0.05; Student’s t test)
doi:10.1371/journal.pone.0010297.g001
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Figure 2. Germinal center formation after immunization. Popliteal draining lymph nodes were harvested at day 7 after injection with VEE/SIN-
H, FI-MV, SRBCs or PBS. Cryosections (10mm) were stained with PNA-FITC for GC B cells (green) and with PE-conjugated antibody to IgD for follicular B
cells (red). Representative images are 2006magnification (A). GCs detected by histology were enumerated and presented as the mean +/2 S.D. of at
least 5 sections from one mouse (n.d.=none detected) (B).
doi:10.1371/journal.pone.0010297.g002
Figure 3. Kinetics of the germinal center response after immunization. Cells from popliteal draining lymph nodes harvested at various times
after immunization with VEE/SIN-H, FI-MV, SRBCs (positive control) or PBS were analyzed for GC B cells by flow cytometry. Cells were stained with
antibody to CD19 and PNA at day 7 (A) and periodically over an 80-day time course (B). All flow cytometry data points represent values from cells
pooled from 2 mice.
doi:10.1371/journal.pone.0010297.g003
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predominantly produced IL-4 with an IFN-c/IL-4 SFC ratio of
0.61 at day 7 and 0.63 at day 14. Responses of splenocytes to MV
antigen stimulation were similar in pattern to those observed in the
dLN, but lower in magnitude (Fig. 6E, F).
To better characterize the CD4
+ T cell response, responses to
known class II-restricted (I-E
d)C D 4
+ T cell epitopes for H, F and N
proteins [65–70], as well as L cell lysates and peptide pools, were
assessed (Fig. 7). VEE/SIN-H–immunized mice produced IFN-c in





Figure 4. Development of antibody-secreting cells in draining lymph nodes and bone marrow after immunization. At various times
after immunization, cells from draining popliteal LNs and bone marrow were collected and analyzed by IgG ELISpot. Total IgG-secreting cells were
measured in the draining LNs (A) and the bone marrow (C), in addition to MV-specific ASCs (B and D). ELISpot plate images of bone marrow
aspirates assayed for MV-specific ASCs at day 80 after immunization (E). The spot area for MV-specific IgG ASCs from the bone marrow at different
times after immunization (F). Wells were loaded with 5.0610
5 unfractionated bone marrow cells. Assays were performed in triplicate (error bars
represent S.D. of assay replicates) with cells pooled from 3 mice.
doi:10.1371/journal.pone.0010297.g004
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MV mice was negligible (Fig. 7A, C, E). However, FI-MV–
immunized mice produced IL-4 in response to stimulation with
both H- and F-containing L cell lysates 7 days after immunization
(Fig. 7B). The response to H was 8.5% of the IL-4 response after
MVL stimulation at the same time point (Fig. 6B). F-specific
secretion of IL-4 was stimulated by individual class II peptides F1
and F2, as well as the F peptide pool through day 21 (Fig. 7B, D, F)
and F-specific IFN-c secretion at day 7 (Fig. 7A), represented
26.5% of the IFN-c-secreting cells stimulation by MVL.
B cell recall responses to H
To assess the development of H-specific memory B cells, VEE/
SIN-H was administered 81 days after initial immunization with
FI-MV, VEE/SIN-H or PBS. VEE/SIN-H–immunized mice
showed increased production of anti-MV antibody (Fig. 8A) and
anti H antibody (Fig. 8B) by 4 days after a secondary
immunization with VEE/SIN-H (p,0.05). FI-MV–immunized
mice did not show an increase in anti-H titer until day 8 and the
kinetics and magnitude were similar to the PBS control mice
(Fig. 8B). At day 12, dLNs were collected and assayed for MV-
specific ASCs (Fig. 8C, D). Mice immunized with FI-MV and then
boosted with VEE/SIN-H had MV-specific ASCs at a level similar
to that of control mice initially injected with PBS, while VEE/
SIN-H-immunized mice had a large number of MV-specific ASC
comparable to the numbers of IgG ASC.
Discussion
Measles remains a worldwide public health concern and is a
particular threat to health in early life. Recent efforts have focused
on developing a vaccine that will circumvent the maternal
antibody barrier for immunizing young children, while avoiding
problems encountered with FI-MV, and on new routes of delivery
for the current vaccine. To better understand the problems with
responses to FI-MV, as well as to obtain information on the
immune response to a promising new vaccine, we compared the
responses of mice to FI-MV and VEE/SIN-H. The immune
responses to FI-MV were characterized by a slow induction of GC
formation, low avidity MV-specific IgG with IgG1.IgG2a, high
levels of antibody-secreting B cells in the dLNs, and T cells that
produced more IL-4 than IFN-c in response to stimulation with
MV. VEE/SIN-H rapidly induced GC formation in the dLN,
high avidity MV-specific IgG with IgG2a.IgG1, neutralizing
antibody and T cells that produced IFN-c and IL-4 both
spontaneously ex vivo and in response to stimulation with H. FI-
MV did not induce H-specific antibody, memory B cells or plasma
cells and thus did not induce neutralizing antibody. Instead, FI-
MV induced a low avidity antibody to N. Thus, these measles
vaccines differed in antibody specificity, isotype, avidity, local B
cell responses and T cell cytokine profiles.
The most important correlate of vaccine-induced protection
from measles is the presence of high avidity neutralizing antibody
at the time of exposure to wild type MV [37]. This study has
Figure 5. Protein-specific antibody responses to vaccine antigens. Serum IgG specific for MV H (A), F (B) and N (C) proteins over a 125-day
time course measured by EIA. H-specific ASCs from the bone marrow measured by ELISpot at day 125, represented as an index of total spot number
multiplied by spot area (D). Serum antibody data points represent the mean +/2 S.D. of 3 individual mice. IgG ELISpot data are generated from cells
pooled from 3 mice.
doi:10.1371/journal.pone.0010297.g005
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replicon particle vaccine VEE/SIN-H resulted in a LN environ-
ment that promoted avidity maturation of antibody to H and
the production of ASCs that homed to the bone marrow, a
site of sustained production of antibody for humoral memory
[64,71–75].
FI-MV–immunized mice developed a poor response to the H
protein. Antibody to H was not detected by EIA or by PRN and T
cells did not respond to H peptide stimulation with production of
IFN-c or IL-4. Furthermore, boosting of FI-MV-vaccinated mice
with VEE/SIN-H did not elicit an anamnestic B cell response to
H. Lack of antibody to the H envelope glycoprotein is consistent
with the absence of neutralization capacity. FI-MV induced
abundant antibody to N, a viral protein that resides in the interior
of virion and is highly structured [76]. These differences in viral
protein immunogenicity may reflect differential stabilization by
formalin and methylene bridges generated by formaldehyde
polymers [77] may alter available B cell epitopes. Highly ordered
structures such as N may allow for more epitope-preserving
formalin crosslinking. Early studies of immune responses to
inactivated measles vaccine in humans reported a lack of antibody
to F [78], but antibodies to H were detected in vaccinees and also
in monkeys immunized with FI-MV. However, these antibodies
waned quickly leaving individuals susceptible to MV infection
Figure 6. Measles virus-specific T cell responses after immunization. IFN-c (A) and IL-4–secreting cells (B) from the dLN were measured at
day 7 after immunization with VEE/SIN-H or FI-MV. Media-only stimulation represents ex vivo spontaneous secretion. This value has been subtracted
from the MVL stimulation values. At days 7, 14 and 21 after immunization, cells from dLNs (C, D) and the spleen (E, F) were evaluated for IFNc and IL-
4 secretion after ex vivo stimulation with MVL antigen in ELISpot assays. Spot-forming cells are per 5610
5 total cells. Assays were performed in
triplicate (error bars represent S.D. of assay replicates) with cells pooled from 3 mice.
doi:10.1371/journal.pone.0010297.g006
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antigens and lack of an H response suggests denaturation by the
combination of formalin-treatment, alum precipitation and time.
The adjuvant activities of alum and alphavirus particles are
distinct. Alum-precipitated antigens are taken up by dendritic cells
(DCs) where they activate the NLRP3 inflammasome for caspase
1-dependent production of IL-1b, possibly through increasing
local concentrations of uric acid [79]. Chemokines CCL2 and
CCL11 are produced within hours resulting in attraction of
inflammatory cells to the site. Early production of IL-4 inhibits the
differentiation of Th1 cells resulting in a Th2-biased response that
supports B cell and antibody responses [80,81]. However, it is
unclear why this Th2-dominant environment for B cell differen-
tiation resulted in an inferior antibody response that was not
Figure 7. Protein-specific T cell responses after immunization. Cytokine secretion as a readout for recognition of class-II restricted CD4
+ T cell
MV epitopes for H (H1, H2), F (F1, F2) and N (N1) proteins, as well as complete peptide pools for H and F proteins, was measured for IFN-c (A, C, E)
and IL-4 (B, D, F) in cells from the dLN by ELISpot at 1, 2 and 3 weeks after immunization. Negative controls were an irrelevant influenza HA peptide
(I1 - I-E
d) and media-only and ConA-stimulated cells (not shown) served as a positive control (n.d.=not determined). Negative controls (media-only)
were subtracted to discount cells that spontaneously produced cytokines and to emphasize antigen-specific reactivity. Spot-forming cells are per
5610
5 total cells. Assays were performed in triplicate (error bars represent S.D. of assay replicates) with cells pooled from 3 mice.
doi:10.1371/journal.pone.0010297.g007
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humans.
In contrast, alphavirus replicon particles target DCs [82] and
feature viral molecular patterns with intrinsic adjuvant effects
[53,83]. Replicons expressing heterologous proteins or null-
replicons co-administered with protein antigens induce the rapid
local production of cytokines and chemokines including IFN-b, IL-
5, IL-6, TNF-a, CCL4, CCL5 and CXCL10 [54,84,85].
Interestingly, these vaccines induce production of IgA and CD8
+
T cells that appear at mucosal sites [52,54,86,87], properties likely
to be of benefit for a vaccine against measles.
A primary difference between the vaccines was in the
maturation of antibody avidity. VEE/SIN-H and FI-MV initiated
GC responses of similar magnitude. GCs are the sites of somatic
hypermutation of variable region DNA and selection for B cells
that possess antigen receptors with high affinity [88]. FI-MV
induced a large extrafollicular B cell response, but there was no
evidence of a T-independent response, as no MV-specific IgG3
was detected and antibody responses of XID mice were similar to
those of control mice (data not shown). GCs in the dLNs of FI-
MV-immunized mice peaked approximately 7 days later than GCs
in the lymph nodes of VEE/SIN-H and SRBC–immunized mice.
This late time course is observed with other alum-precipitated
vaccines and perhaps reflects the quality of the T cell response or
the ‘‘depot effect’’ commonly attributed to this adjuvant [89–91].
GC reactions for most T-dependent antigens peak around 10–12
days [92], but instances of long-lived GCs have been linked to

















Figure 8. Hemagglutinin-specific antibody-secreting cell recall responses. Mice immunized with FI-MV, VEE/SIN-H or mock-immunized with
PBS were given VEE/SIN-H at day 81 after primary immunization, bled at days 4 and 8 post-secondary immunization and sacrificed at day 12. EIAs
were performed to measure serum antibody with reactivity against MVL (* P,0.05; Student’s t test) (A) and H (B) induced in the recall response up to
12 days after administering VEE/SIN-H. ASCs in the draining LNs were assayed for total IgG and MV-specific antibody secretion by ELISpot (C, D)1 2
days after secondary immunization. Serum antibody data points represent the mean +/2 S.D. of 3 individual mice. IgG ELISpots were performed in
triplicate (error bars represent S.D. of assay replicates) with cells pooled from 3 mice.
doi:10.1371/journal.pone.0010297.g008
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formation. This lag may be due to the dilution of emerging avid
clones by earlier short-lived ASCs [94] secreting unmatured IgG
or to continued avidity maturation at sites outside GCs.
We conclude that a primary reason for the failure of FI-MV is
likely to be the poor preservation of the immunogenicity of the
MV H protein. FI-MV also induced poor avidity maturation of
antibody to N and elicited a type 2-skewed T cell response. In
contrast, VEE/SIN-H induced a robust and balanced T and B cell
response to the MV H protein that resulted in durable production
of affinity-matured neutralizing antibody. Future studies of this
vaccine will require consideration of the addition of other MV
antigens, in addition to manufacturing, cost, safety and immuno-
genicity in humans.
Materials and Methods
Mice, vaccines and immunization
Eight-to-ten week-old female BALB/c (Charles River Labora-
tories, Wilmington, MA), mice were used. Alum-precipitated FI-
MV prepared in the 1960s (Pfizer, Terre Haute, IN; gift of Albert
Kapikian, National Institutes of Allergy and Infectious Diseases,
Bethesda, MD) was given at a dose of 50 mL per mouse. A
chimeric VEE/SIN-based replicon particle vaccine [48] engi-
neered to express MV Edmonston strain H [55] was diluted in
40 mg/mL lactose/PBS and given at a dose of 1.25610
6 particles,
previously shown to be optimal for alphavirus replicon particles
expressing H [11]. Control mice were injected with PBS or with 1–
5610
9 PBS-washed SRBCs, (Colorado Serum Company, Denver,
CO). All immunizations were administered subcutaneously
(standard for measles vaccines) in both hind feet to facilitate
access to the dLNs. At various times after immunization, mice
were anesthetized with isoflurane (Abbott Laboratories, North
Chicago, IL) and blood, draining popliteal LNs, spleens and bone
marrow were collected. Mice were maintained under specific
pathogen-free conditions and used in accordance with protocols
approved by the Johns Hopkins University Animal Care and Use
Committee.
MV Antigens
For total MV protein, a lysate of MV-infected Vero cells (MVL)
(Advanced Biotechnologies Inc., Columbia, MD) was used. For
MV H and F envelope proteins, lysates were prepared from L929
murine fibroblasts expressing either H or F [95] (a gift from Fabian
Wild, Pasteur Institute, Lyon, France). The BaculoDirect
TM
Baculovirus Expression System (Invitrogen, Carlsbad, CA) was
used to generate full-length N protein from infected Sf9 insect
cells. All MV proteins were from the Edmonston strain and were
used in immunoassays as clarified lysates.
Twenty-mer peptides (with 11 amino acid overlaps) covering the
sequences of H and F were synthesized using solid-phase peptide
chemistry by the JHU Synthesis and Sequencing Facility and
peptides for each protein were pooled. In addition, individual
peptides corresponding to previously mapped MHC-II-restricted
(I-E
d) epitopes of MV H, F and N proteins [65–69] were
synthesized: H – LYKSNHNNVYWLTIP (aa 446–460; H1),
YSPGRSFSYFYPFRL (aa 546–560; H2); F – LLGILESRGI-
KARIT (aa 256–270; F1), PVVEVNGVTIQVGSR (aa 421–435;
F2); N – YAMGVGVELEN (aa 335–345; N1). All peptides were
based on the MV Edmonston sequence.
Antibody Assays
To measure MV-specific IgG, 96-well Maxisorp
TM ELISA
plates (Nalge Nunc International, Rochester, NY) were coated
with MVL, lysates of L cells expressing H or F or with baculovirus-
generated N diluted in 50 mM sodium bicarbonate buffer,
pH 9.6. Wells were coated overnight at 4uC, plates were blocked
with 2% non-fat dry milk and individual serum samples were
diluted ten-fold in 1% non-fat dry milk for analysis. MV-specific
binding was detected with horseradish peroxidase (HRP)-labeled
goat anti-mouse IgG, IgG1, IgG2a or IgG3 (Southern Biotech,
Birmingham, AL) and 3,39, 5,59-tetramethylbenzidine (Sigma) as
the enzymatic substrate. For avidity measurements, the enzyme
immunoassay (EIA) was modified to include a 0-3.5M ammonium
thiocyanate (NH4SCN) wash in 0.5M steps to dissociate bound
IgG [96,97]. The avidity index is the concentration of NH4SCN at
which 50% of the antibody was eluted.
Neutralizing antibody was measured by plaque reduction (PRN)
as previously described [98] using the Chicago-1 strain of MV for
infection of Vero cells to calculate 50% neutralization titers. Data
are reported as geometric mean titer for 3 animals at each time of
sampling. The assay was run in triplicate for each sample.
Histology
Freshly harvested, OCT-embedded draining LNs were cryosec-
tioned to 10mm thickness on a Microm HM-500 cryostat
(Walldorf, Germany) and fixed in cold acetone. Sections were
blocked with 10% normal rat serum (Chemicon, Temecula, CA)
followed by staining with PNA-biotin (10 mg/mL) (Vector
Laboratories, Burlingame, CA) and rat anti-mouse IgD-PE
(1 mg/mL) (Southern Biotech) overnight at 4uC. PNA
+ cells in
GCs were identified with streptavidin conjugated to Alexa
Fluor
TM 488 (5 mg/mL, Invitrogen). Sections were mounted with
Shur-Mount (EM Sciences, Ft. Washington, PA) and viewed
under a Nikon E800 fluorescent microscope. Images of sections
from each mouse were analyzed for GCs using SPOT Advan-
ced
TM software (Diagnostic Instruments, Sterling Heights, MI).
Flow Cytometry
To identify GC B cells, draining LN cells were incubated with
purified rat anti-mouse CD16/CD32 (5 mg/mL) (BD Biosciences)
to block Fc receptors and then stained with Alexa Fluor
TM 647-
conjugated rat anti-mouse CD19 (2 mg/mL) (BD Biosciences) and
FITC-conjugated PNA (Sigma) at 0.2 mg/mL in 0.1% BSA/PBS
with 0.02% NaN3. Samples were analyzed on a FACSCalibur flow
cytometer (BD Biosciences) and the data were evaluated using
Flowjo
TM software v8.7.3 (Tree Star, Ashland, OR).
ELISpot Assays
96-well Multiscreen
TM HTS HA Opaque ELISpot plates
(Millipore, Billerica, MA) were used. Plates were coated with
MV antigens (as described above) or with purified goat anti-mouse
Ig (Southern Biotech) at 10 mg/mL and blocked in complete
RPMI-10 media for 2 h at 37uC. Single-cell suspensions from
dLNs or bone marrow were plated at various concentrations in
fresh media and incubated for 8 h at 37uC, 5% CO2. Bone
marrow aspirates were treated with RBC lysis buffer (Sigma) and
washed prior to plating. After incubation, bound IgG was detected
with HRP-labeled goat anti-mouse IgG (1:5,000) (GE Healthcare,
Piscataway, NJ) and developed with stable diaminobenzidine
(DAB) (Invitrogen) and read on an ImmunoSpot
TM plate reader
(Cellular Technology, Shaker Heights, OH). The data were
analyzed with ImmunoSpot
TM 2.0.5 software.
For assays of IFN-c and IL-4–secreting cells, ELISpot assays
were performed as above using plates coated with purified rat anti-
mouse IFN-c or IL-4 capture antibodies (BD Biosciences) at 5 mg/
mL. Biotin-conjugated rat anti-mouse IFN-c or IL-4 detection
antibodies (2 mg/mL) (BD Biosciences) and avidin-D-HRP
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were incubated for 48 h at 37uC, 5% CO2. Ex vivo culture
stimulants for IFN-c and IL-4 ELISpot assays included MVL
(1:100), L(H) lysate (1:20), L(F) lysate (1:20), H and F peptide pools
at 1 mg/mL and individual MV peptides (H1, H2, F1, F2, N1)
at 5 mg/mL (described above). Controls included an irrelevant
I-E
d-restricted peptide from the hemagglutinin of influenza A–
KYVKQNTLKL (I1) [70] at 5 mg/mL, normal L cell lysate
(L(-)) diluted 1:20 and media alone, while concanavalin A-
stimulated cells (5 mg/mL) (Sigma) served as a positive control.
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